APIM Therapeutics AS, a Trondheim Norway-based early-stage therapeutic company, has closed an additional seed funding round.
The investment is provided by existing backer Sarsia Seed AS.
Based on an original discovery by Prof. Marit Otterlei and co-inventors at NTNU, APIM Therapeutics is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), an emerging cancer drug target implicated in the regulation of cellular responses to DNA damage and stress.
The company intends to use the funds to pursue further in vivo testing of its lead drug candidate, ATX-101, which is being developed as a novel anti-cancer treatment targeting DNA repair and cell cycle control in tumor cells.
APIM Therapeutic’s shareholders also include NTNU Technology Transfer AS.
The company is led by CEO Konstantinos Alevizopoulos.